LH-1802 / Lianhuan Pharma, Shanghai Inst. of Materia Medica - LARVOL DELTA

Clinical trial of new drug for acute myeloid leukemia or myelodysplastic syndrome: LH-1802 capsule [Google translation] (Sohu.com) - "Preclinical studies have shown that LH-1802 has excellent LSD1 inhibitory activity and selectivity, good pharmacokinetic properties and safety in rats and dogs, and is a safe, effective, quality-controlled anti-tumor clinical candidate drug with good drug development prospects. The approval of the clinical trial of this product provides a safe and effective potential treatment option for patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome."

New trial • Acute Myelogenous Leukemia • Myelodysplastic Syndrome

Lianhuan Pharmaceutical: LH-1802 Capsules Approved for Clinical Trial [Google Translation] (Daily Economic News - NBD) - "Every AI newsletter, on November 8th, Lianhuan Pharmaceutical announced that the company has recently received the 'Drug Clinical Trial Approval Notice' for LH-1802 capsules (specification: 0.1mg 0.5mg 2mg) approved and issued by the National Medical Products Administration. Book" and will carry out clinical trials for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in the near future. LH-1802 is a class I anti-tumor innovative drug. The proposed indication is hematoma or solid tumor."

Non-US regulatory • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology